Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given signed consent to take part in the study
• People who have been diagnosed with a specific type of chest lining cancer called epithelioid malignant pleural mesothelioma (MPM) that cannot be removed by surgery, confirmed by a tissue sample (any stage)
• People aged 18 or older at the time of signing consent
• People who are generally well enough to carry out daily activities with little or no limitation, as rated by a standard medical scale (WHO performance status 0 or 1)
• People whose blood counts and organ function meet specific minimum levels at screening — including white blood cells, platelets, red blood cells, liver markers, kidney function, and blood clotting markers (confirm specific values with trial site)
• People who test negative for HIV at screening
• People who test negative for active hepatitis B infection at screening, or who have certain hepatitis B antibody results that are followed up with additional testing showing no active virus
• People who test negative for hepatitis C at screening, or who have a positive antibody test followed by a negative RNA test confirming no active hepatitis C virus
• People who the treating doctor believes are willing and able to follow the study plan
• Women who could become pregnant must have a negative pregnancy test at screening and must agree to use highly effective contraception before, during, and for at least five months after the last dose of atezolizumab, or at least 100 days after the last vaccine dose — whichever period is longer
• Men must agree to use effective contraception before, during, and for at least 100 days after the last study treatment

Who may not be able to join:

• People who have had another cancer within the past 3 years, except for certain low-risk cancers that were fully treated (such as some skin cancers, early-stage cervical changes, or early-stage uterine cancer) (confirm with trial site)
• People who have brain or spinal cord spread of their cancer that is causing symptoms, has not been treated, or is actively getting worse — though people with previously treated, stable brain spread who meet specific additional conditions may still be considered (confirm with trial site)
• People who have had cancer spread to the thin lining surrounding the brain and spinal cord (leptomeningeal disease)
• People with an active or past autoimmune disease or immune system disorder — though some conditions such as well-controlled thyroid disease, Type 1 diabetes on insulin, or mild, stable skin conditions may still be considered (confirm with trial site)
• People with a history of certain lung inflammation conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-induced lung inflammation, or who show signs of active lung inflammation on a chest scan at screening
• People who have had a significant heart or blood vessel event — such as a heart attack or stroke — within 3 months before starting the study, or who have an unstable heart rhythm or unstable chest pain
• People who have had a major surgical procedure (other than for diagnosis) within 4 weeks before starting the study, or who are expected to need major surgery during the study
• People who have had a severe infection within 4 weeks before starting the study, or who have any active infection that could affect their safety
• People who have already received any treatment for their MPM
• People who have taken antibiotic treatment (not preventive) by mouth or through a drip within 2 weeks before starting the study
• People who have previously received a stem cell or organ transplant from another person
• People who have used any experimental treatment within 28 days before enrolling in the study
• People who are pregnant or breastfeeding — women who are breastfeeding must stop before the first dose and for at least 100 days after the last dose
• People who have received a live vaccine within 4 weeks before starting the study, or who expect to need one during atezolizumab treatment or within 5 months of the final atezolizumab dose
• People currently receiving antiviral treatment for hepatitis B
• People who have previously been treated with certain types of immune-based therapies, including anti-CTLA-4, anti-PD-1, or anti-PD-L1 drugs, or CD137-activating treatments
• People who have received immune-suppressing medications — such as steroids, methotrexate, or similar drugs — within 2 weeks before starting the study, or who are expected to need them during the study (some exceptions apply — confirm with trial site)
• People who have received immune-stimulating medications such as interferons or interleukin-2 within 4 weeks (or longer, depending on the drug) before starting the study
• People with a history of a severe allergic reaction to certain types of laboratory-made antibody treatments
• People with a known allergy to any ingredient in atezolizumab or to products made using a specific cell type used in its manufacture (Chinese hamster ovary cells)
• People with any other physical or psychological condition that the treating team believes could make the study treatments unsafe, affect the person's ability to follow the study plan, or increase the risk of complications

Important: Always verify eligibility with the trial site directly before applying.